Introduction: Cerebral malaria which occurs during the active infection is the most common neurological complication of malaria. Other complications including post-malaria neurological syndrome (PMNS) can rarely occur following complete recovery from the disease. We report a case of post-malaria neurological syndrome in a Tunisian patient. Case presentation: A 26-year-old Tunisian man with no past medical history was admitted in 2016 for a muscle weakness of the 4 limbs, seizures, tetraparesis and myoclonus which appeared after he returned from Côte d’Ivoire where he had been treated three weeks ago for Plasmodium falciparum malaria with favorable outcome. Blood smears for malaria were negative. Brain MRI showed multiple hypersignal cerebral lesions. Investigations didn’t show any infectious, metabolic, toxic, vascular or tumoral etiology. Thus, the diagnosis of PMNS was considered. The patient was treated with methylprednisolone with favorable outcome. Two years later, he was completely asymptomatic. Conclusion: PMNS should be considered in patients with neurological symptoms occurring within two months of cured acute disease in which blood smears for malaria are negative and other etiologies have been ruled out. In most cases, the disease is self-limited while in severe cases corticosteroid therapy should be prescribed with favorable outcome. Keywords: Post-malaria neurological syndrome; immunologic; corticosteroid.
Background Anti-viral therapy is not routinely recommended for chronic hepatitis B virus (HBV) infection, in patients who have persistently elevated serum HBV DNA level (>2000 IU/mL), normal alanine aminotransferase (ALAT) and without significant liver fibrosis, defining the indeterminate phase. The objective of the study is to identify the factors associated with the progression of liver fibrosis in chronic HBV infected patients in the indeterminate phase. Methods This is cross-sectional study, conducted in Infectious Disease and Hepato-gastroenterology departments of Farhat Hached university hospital, between January 2008 and January 2022. We have included the Ag HBs (+) patients initially not treated, presenting at the time of the initial evaluation: a viral load> 2,000 IU/L for at least six months, normal ALAT (<40UI) and a fibrosis score F0 and/or F1 (in liverbiopsy or FibroScan). Univariate and logisticreg ression analysis were performed to identify the factors associated with liver fibrosis progression. Results In total, 97 patients were included, with a median age of 32.9± 9.1 years, and a female predominance (sex ratio M/F=0.64). Progression of fibrosis was observed in 16 patients (16.5%) with a mean delay of 70.9±41.1 months. In the univariate analysis, factors associated with progression of fibrosis were the presence of comorbidities (p=0.001), the high initial viral load (p=0.004), the appearance of cytolysis (p=0.001) and the increase in viral load (p=0.002), during follow-up. The AUROC of the initial viral load was 0.664 (95%CI: 0.500-0.820). An intial viral load at 8090 UI/l was associated with the progression of fibrosis with a sensibility of 70.3% and specificity of 63%. Conclusion Factors associated with progression of fibrosis in the indeterminate phase of chronic HBV infection were the presence of comorbidities, and changes of ALAT during follow-up. This leads us to consider extending the therapeutic indications to this group of patients.
31 December 2023 in The Journal of Infection in Developing Countries
Introduction: The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in around 1 million COVID-19 infection cases and over 29,000 deaths in Tunisia thus far. There is great variability in the prevalence of asthma among patients with COVID-19, but the impact of asthma on patients with COVID-19 is not clear. We sought to describe the clinical features of Tunisian patients with COVID-19 and to compare asthmatic and non-asthmatic patients. Methodology: This retrospective study included 675 Tunisian patients who were hospitalized with COVID-19. Clinical characteristics were collected from medical records. Bivariate analyses and multivariate regression models were used to assess the associations between asthma and the risk of severe symptoms, including death/recovery. Results: The prevalence of asthma in the sample was 14.5%. The results show that asthmatic patients with COVID-19 have significantly less severe symptoms and better outcomes than non-asthmatic patients. Conclusions: Asthma was not found to be associated with higher severity or worse prognosis among patients with COVID-19 in Tunisia.
Cystitis is a very common infection of the lower urinary tract. Women are typically affected, and more than 30 percent will experience at least one episode of cystitis in their lifetime. The diagnosis of this condition and its management are widely known and applied in the outpatient healthcare setting. However, recurrent cystitis, associated with a significant morbidity, is more challenging since their diagnostic evaluation, management and prevention differ significantly between disciplines. Several treatment and prevention options are offered to women with recurrent cystitis. Antibiotic prevention and treatment options should not be first-line, given the importance to limit resistance development and efficacy of alternatives in most situations. The proposed chapter is a narrative review on the current state-of-the-art for the diagnostic evaluation, management and prevention of recurrent cystitis, and aims to discuss other issues and aspects that could be addressed for an optimal management of this condition.
Background: The outbreak of the coronavirus disease 2019 (COVID-19) has become an evolving worldwide health crisis. With the rising prevalence of diabetes mellitus has come an increasing awareness of their impacts on infectious diseases, and the risk for postinfection complications and mortality from critical infections. Objective: The objective of this study was to evaluate the prevalence and impact of diabetes mellitus on the severity and mortality of COVID-19. Methods: Data of laboratory-confirmed hospitalized patients at the COVID-19 unit between September 2020 and August 2021 were analyzed, in a cross-sectional study. The population was classified into two groups: COVID-19 patients with and without diabetes. Primary outcomes were the overall length of hospital stay, the admission to the ICU, and death. The association between diabetes and death was assessed in a Cox proportional hazards model. Results: A total of 866 patients were included. There were 270 (31.2%) patients with diabetes. Diabetic patients were more likely to have hypertension (58.1 vs. 33.4%), cardiovascular disease (18.5 vs. 10.4%), and dyslipidaemia (17.8 vs. 7.2). Overall, 263 patients died, among them only 86 in the diabetic group (P=0.523). Patients with diabetes had a higher risk of developing complications (P<0.001). Multivariate Cox regression analysis showed that diabetes was not significantly associated with death [HR (95% CI): 1.253 (0.963–1.631)]. Conclusion: Diabetes was associated with a greater risk of complications in patients with COVID-19. Special attention to diabetic patients during treatment must be given to avoid these complications.